This is the text extract for October Tender Notification; Contact: Notifications, browse documents here.

---

31 October 2011

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and the 2009/10 Invitation to Tender, dated 4 December 2009. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A462403 - qA18036

Page 1 of 4

---

2010/11 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Current subsidy New subsidy and price Date of Sole supply listing/subsidy brand (Supplier) change for tender winning brand Date of reference pricing of other listed brands Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting Levlen ED Microgynon 30 ED (Bayer) 1 April 2012 1 June 2012 1 September 2012 Monofeme Nordette 28 (Pfizer) 1 March 2012 1 March 2012 1 May 2012 1 May 2012 1 August 2012 1 August 2012 Maxalt Melt (MSD) Actigall (Novartis)

Ethinyloestradiol with levonorgestrel

Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets, blister pack

$6.62

$2.45

Ava 30 ED (Arrow)

Rizatriptan Ursodeoxycholic acid

$25.32 Orodispersible tab 10 mg; 30 tablets, blister pack (per 3 tablets) Cap 250 mg; 100 capsules, blister pack $179.00

$18.00 (per 30 tablets) $71.50

Rizamelt (Mylan) Ursosan (ABM)

2.

Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows: Chemical name Presentation; Pack size and type Inj long-acting 100 mg per ml, 10 ml; 1 vial Current subsidy and price $61.41 New subsidy and price $76.50 Sole supply brand (Supplier) DepoTestosterone (Pfizer) Date of subsidy change Sole Subsidised Supply date

Testosterone cypionate

1 December 2011

1 March 2012

A4624030317 - qA18036

Page 2 of 4

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Current pack price New pack price $18.00 (per 30 tablets) $71.50 Hospital Supply Brand (Supplier) Rizamelt (Mylan) Ursosan (ABM) DV Limit Date of listing/price change for tender winning brand 1 March 2012 Hospital Supply Status date (and delisting of other listed brands) 1 May 2012 Brand (Supplier) to be delisted Maxalt Melt (MSD) Actigall (Novartis)

The decisions were as follows:

Chemical Name

Rizatriptan Ursodeoxycholic acid

$25.32 Orodispersible tab 10 mg; 30 tablets, blister pack (per 3 tablets) Cap 250 mg; 100 capsules, bllister pack $179.00

1%

1%

1 March 2012

1 May 2012

4.

Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical Name Testosterone cypionate Presentation; Pack size and type Inj long-acting 100 mg per ml, 10 ml; 1 vial Current pack price $61.41 New pack price $76.50 Hospital Supply Brand (Supplier) DepoTestosterone (Pfizer) DV Limit 1% Date of price change Hospital Supply Status date

The decisions were as follows:

1 December 2011

1 February 2012

2009/10 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2013 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

A4624030317 - qA18036

Page 3 of 4

---

Chemical Name

Presentation; Pack size and type Tab 25 mg; 112 tablets, bottle

Current New subsidy subsidy and and price price $243.00 $178.00

Sole supply brand (Supplier) Motetis (Douglas)

Date of listing/subsidy change for tender winning brand 1 March 2012

Date of reference pricing of other listed brands 1 May 2012

Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 August 2012 Xenazine 25 (AFT)

Tetrabenazine

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Tab 25 mg; 112 tablets, bottle Pack price $178.00 Hospital Supply Brand (Supplier) Motetis (Douglas) DV Limit 1% Listing date 1 March 2012 Hospital Supply Status date 1 May 2012

The decisions were as follows:

Chemical Name Tetrabenazine

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name Ethinyloestradiol with levonorgestrel Line Item Tab 30 mcg with levonorgestrel 150 mcg

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A4624030317 - qA18036

Page 4 of 4